11 completed, 6 active not recruiting, 6 recruiting, 2 terminated. 29 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 29 | Completed 11, Active not recruiting 6, Recruiting 6, Terminated 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow CP protocol: new trials by email Literature Review of CP protocol trials Research Report on CP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer medroxyprogesterone acetate tablets OR megestrol acetate, Cisplatin, Carboplatin + Paclitaxel - Endometrial Cancer, Uterine Neoplasms | Phase 3 | Recruiting | University College, London | 600 | 2026-06-29 | 2026-09-21 |
| A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. EIK1001, Pembrolizumab (KEYTRUDA®), Placebo - Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC | Phase 2 / Phase 3 | Recruiting | Eikon Therapeutics | 750 | 2026-06-15 | 2026-11-03 |
| SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） SYS6010 injection, Enlonstobart injection, Tislelizumab injection - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 500 | 2026-06-02 | 2026-06-11 |
| A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin - Non-Small Cell Lung Cancer With HER2- Mutations | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 300 | 2024-07-29 | 2026-01-21 |
| Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin - Melanoma | Phase 3 | Recruiting | Shanghai Kechow Pharma, Inc. | 165 | 2023-11-02 | 2024-06-28 |
| Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line Carboplatin-Paclitaxel, Dostarlimab - Endometrial Cancer | Phase 3 | Active not recruiting | ARCAGY/ GINECO GROUP | 260 | 2022-04-15 | 2026-11-06 |
| Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT nab-Paclitaxel+carboplatin, Paclitaxel+carboplatin - Breast Cancer | Phase 3 | Recruiting | Shengjing Hospital | 1498 | 2021-07-19 | 2021-07-20 |
| Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer Paclitaxel, Carboplatin, debulking surgery - Ovarian Cancer | Phase 3 | Unknown | Fudan University | 200 | 2021-07-16 | 2022-05-12 |
| Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Esophagectomy - Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | Karolinska University Hospital | 1020 | 2020-11-27 | 2025-03-06 |
| Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients Bevacizumab, Durvalumab, Olaparib - Advanced Ovarian Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1407 | 2019-01-04 | 2026-07-07 |
| Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer Durvalumab, Placebo, Cisplatin/ Etoposide - Non-Small Cell Lung Cancer | Phase 3 | Completed | AstraZeneca | 328 | 2018-03-29 | 2026-07-14 |
| Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer Doxorubicin Hydrochloride Liposome Injection+carboplatin, paclitaxel +carboplatin - Ovarian Cancer | Phase 3 | Unknown | Hunan Cancer Hospital | 338 | 2017-08-01 | 2021-04-08 |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Chemotherapy, Rucaparib - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 349 | 2017-03-01 | 2023-06-09 |
| Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin - Non Small Cell Lung Carcinoma NSCLC | Phase 3 | Active not recruiting | AstraZeneca | 669 | 2017-01-02 | 2026-06-11 |
| Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin - Non Small Cell Lung Carcinoma NSCLC | Phase 3 | Active not recruiting | AstraZeneca | 953 | 2015-11-03 | 2026-08-06 |
| Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, Carboplatin paclitaxel plus concurrent radiotherapy - Esophageal Cancer, Adenocarcinoma, Esophageal | Phase 2 / Phase 3 | Completed | Dr. Gordon Buduhan | 29 | 2015-09-01 | 2024-08-28 |
| Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin - Non-Small-Cell Lung Carcinoma NSCLC | Phase 3 | Active not recruiting | AstraZeneca | 1118 | 2015-07-21 | 2026-08-06 |
| Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy Docetaxel Cyclophosphamide, Cyclophosphamide Fluorouracil Epirubicin Docetaxel, Epirubicin Cyclophosphamide Paclitaxel - Primary Breast Cancer | Phase 3 | Completed | Fudan University | 1570 | 2010-06-01 | 2020-05-19 |
| A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer Paclitaxel + Carboplatin, Paclitaxel only - Triple Negative Breast Cancer | Phase 3 | Active not recruiting | Tata Memorial Hospital | 720 | 2010-04-01 | 2026-10-02 |
| Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide, Docetaxel, cyclophosphamide - Breast Cancer | Phase 3 | Terminated | Shanghai Jiao Tong University School of Medicine | 102 | 2009-07-01 | 2016-11-22 |
Showing 20 of 29. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Ovarian Neoplasms (6) · Breast Neoplasms (3) · Carcinoma, Ovarian Epithelial (3) · Fallopian Tube Neoplasms (3) · Endometrial Neoplasms (2) · Melanoma (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Carcinoma (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Recurrence (1)
AstraZeneca (5) · Fudan University (2) · AGO Study Group (1) · ARCAGY/ GINECO GROUP (1) · Bayer (1) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · CTI BioPharma (1) · Danish Breast Cancer Cooperative Group (1) · Dr. Gordon Buduhan (1) · Eikon Therapeutics (1) · Hunan Cancer Hospital (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · Japanese Gynecologic Oncology Group (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Karolinska University Hospital (1)
China (11) · United States (10) · Canada (8) · South Korea (8) · France (7) · Poland (7) · Australia (6) · Germany (6) · Hungary (6) · Japan (6) · Spain (6) · United Kingdom (6) · Brazil (5) · Italy (5) · Russia (5)
Andreas du Bois, MD, PhD (1) · Bent Ejlertsen, M.D. (1) · Caigang Liu, M.D., Ph.D. (1) · Carol Aghajanian (1) · E. Pujade-Lauraine, MD, PhD (1) · Florian Lordick, MD, PhD (1) · Gilberto de Castro (1) · Gordon Buduhan, MD MSc FRCSC (1) · Henning T. Mouridsen, M.D. (1) · Hisao Uejima, MD (1) · Hongqi Tian, phD (1) · J. Herrstedt (1)
PMID 19349552, PMID 19767092, PMID 20733132, PMID 21410972, PMID 21831418, PMID 23948349, PMID 24114964, PMID 24356636, PMID 25541155, PMID 25578377, PMID 32271377, PMID 33775558, PMID 35298906, PMID 35912196, PMID 36806898, PMID 37185961, PMID 38468440, PMID 39442040, PMID 39914419, PMID 40323277, PMID 40966692, PMID 41332393
2015 (2), 2017 (2), 2005 (1), 2016 (1), 2018 (1), 2025 (1)